Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 6, 2014, Pages 1123-1132

  Chiaravalloti, Agostino ^a   Danieli, Roberta ^a   Abbatiello, Paolo ^a   Di Pietro, Barbara ^a   Travascio, Laura ^a   Cantonetti, Maria ^a   Guazzaroni, Manlio ^a   Orlacchio, Antonio ^a   Simonetti, Giovanni ^a   Schillaci, Orazio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

ABVD; Chemotherapy; Deauville score; FDG; Hodgkin's lymphoma; Lymphoma; PET

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; VINBLASTINE; ANTINEOPLASTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HODGKIN DISEASE; HUMAN; LIVER; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PET-CT SCANNER; TREATMENT DURATION; WHOLE BODY PET; ANALYSIS OF VARIANCE; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; VASCULARIZATION;

ADULT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LIVER; MALE; MEDIASTINUM; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; VINBLASTINE;

EID: 84900817388     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2703-0     Document Type: Article

References (28)

1. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160-8.
2. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-9.
3. Zinzani PL, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006;17:1296-300.
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
5. Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 2008;5:543-56.
6. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996;6:225-42.
7. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630-6.
8. Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma 2009;50:1761-4.
9. Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 2013;54:683-90.
10. Ceriani L, Suriano S, Ruberto T, Zucca E, Giovanella L. 18F-FDG uptake changes in liver and mediastinum during chemotherapy in patients with diffuse large B-cell lymphoma. Clin Nucl Med 2012;37:949-52.
11. Boktor RR, Walker G, Stacey R, Gledhill S, Pitman AG. Reference range for intrapatient variability in blood-pool and liver SUV for 18F-FDG PET. J Nucl Med 2013;54:677-82.
12. Groheux D, Delord M, Rubello D, Colletti PM, Nguyen ML, Hindie E. Variation of liver SUV on (18)FDG-PET/CT studies in women with breast cancer. Clin Nucl Med 2013;38:422-5.
13. Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011;152:551-60.
14. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181-200.
15. Schillaci O, Travascio L, Bolacchi F, Calabria F, Bruni C, Cicciò C, et al. Accuracy of early and delayed FDG PET-CT and of contrast-enhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients. Radiol Med 2009;114:890-906.
16. Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol Rev Camb Philos Soc 2007;82:591-605.
17. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Erlbaum; 1988.
18. Robinson PJ. The effects of cancer chemotherapy on liver imaging. Eur Radiol 2009;19:1752-62.
19. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med 2002;346:1417-8.
20. Borchmann P, Engert A. The past: what we have learned in the last decade. Hematology Am Soc Hematol Educ Program 2010;2010:101-7.
21. Rueda Domínguez A, Márquez A, Gumá J, Llanos M, Herrero J, de Las Nieves MA, et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004;15:1798-804.
22. Enger A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-52.
23. Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 2007;18:376-80.
24. Owadally WS, Sydes MR, Radford JA, Hancock BW, Cullen MH, Stenning SP, et al. Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). Ann Oncol 2010;21:568-73.
25. Chiaravalloti A, Pagani M, Di Pietro B, Danieli R, Tavolozza M, Travascio L, et al. Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma? Nucl Med Commun 2013;34:57-63.
26. Jaskowiak CJ, Bianco JA, Perlman SB, Fine JP. Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. J Nucl Med 2005;46:424-8.
27. Chin BB, Green ED, Turkington TG, Hawk TC, Coleman RE. Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol 2009;11:118-22.
28. Batallés SM, Villavicencio RL, Quaranta A, Burgos L, Trezzo S, Staffieri R, et al. Variations of the hepatic SUV in relation to the body mass index in whole body PET-CT studies. Rev Esp Med Nucl Imagen Mol 2013;32:26-32.